Breaking News

You are here » Indian-Commodity  :  Corporate  :  Lupin Receives FDA approval for Potassium Chloride Extended Release Capsules

17-Aug2016

Lupin Receives FDA approval for Potassium Chloride Extended Release Capsules

Lupin's US subsidiary, Gavis Pharmaceuticals LLC., USA (collectively Lupin) has received final approval for its Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) from the United States Food and Drug Administration (FDA) to market a generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq. Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq had US sales of USD 75.4 million as per IMS MAT March 2016 data.

Lupin's Potassium Chloride Extended Release Capsules USP, 8 mEq (600 mg) and 10 mEq (750 mg) are the AB rated generic equivalent of Actavis Labs FL, Inc's Potassium Chloride Extended Release Capsules USP, 8 mEq and 10 mEq. It is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications and in patients with hypokalemic familial periodic paralysis. It is also indicated for the prevention of hypokalemia in patients who would be at a particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.



Related News

View all news

IndiGo planning to launch one-stop flights to Europe: Report

InterGlobe Aviation (IndiGo) is reportedly planning to launch flights to London and other European cities by single stop. The airline is in talks with the airports in Tbilisi which is in Georgia and Baku......

Reliance Infrastructure reports 49% fall in Q2 consolidated net profit

Reliance Infrastructure has reported results for second quarter ended September 30, 2018.The company has reported a fall of 65.66% in its net profit at Rs 204.31 crore for the quarter under review as compared......

Shilpa Medicare gets tentative ANDA approval for Dimethyl Fumarate DR Capsules

Shilpa Medicare has received tentative approval for its ANDA for Dimethyl Fumarate Delayed Release Capsules 120 mg & 240 mg. from USFDA. Dimethyl Fumarate Delayed Release Capsules 120 mg &......

Top News

View all news

Karnataka Bank launches CASA campaign

Karnataka Bank has launched Current & Savings Accounts campaign (CASA) of FY 2018-19 and introduced a new SB scheme 'KBL SB - TASC' a specialized product for Trusts/Associates/Societies/Clubs.Under......

M&M's arm opens manufacturing hub in Bengaluru

Mahindra & Mahindra's (M&M) subsidiary -- Mahindra Electric Mobility has opened its electric technology manufacturing hub set up with an investment of Rs 100 crore in Bengaluru. The plant......

Venus Remedies reports positive result in Phase-3 Clinical Trials for ELORES

Venus Remedies has reported positive Top-Line results in its Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific......